Qualification & Validation
Qualification & Validation
Quality Assurance
Quality Assurance
Regulatory Affairs
Regulatory Affairs
Clinical
Clinical
Lab Services
Lab Services
Vigilance
Vigilance
Software Solutions & Services
Software Solutions & Services
Tox green
Toxicology
Pharma (2)
Pharma & Biotech
Medical Devices (2)
Medical devices
IVD (2)
In vitro diagnostics
Search QbD Group
  • There are no suggestions because the search field is empty.
Aggregate Safety Reporting - Vigilance - QbD Group (1)

Aggregate Safety Reporting

Comprehensive safety reporting tailored to your needs

Aggregate safety reporting is a critical component of pharmacovigilance and post-marketing surveillance. At QbD Group, our One Vigilance services compile, analyze, and deliver safety reports that ensure compliance with global regulatory requirements. Whether it’s IND Annual Reports, Clinical Study Reports, or NDAs, we provide accurate and timely insights to enhance product safety and regulatory success.

Read more

What is aggregate safety reporting?

Aggregate safety reporting involves the periodic collection, analysis, and submission of safety data from multiple sources. These reports provide a holistic view of a product’s safety profile and are essential for ongoing regulatory compliance and risk mitigation. Key types of aggregate safety reports:

  • IND Annual Reports: Documenting safety information from clinical trials for investigational drugs.
  • Clinical Study Reports (CSRs): Comprehensive summaries of clinical trial data.
  • New Drug Applications (NDAs): Safety data submitted for regulatory approval of new drugs.
  • Periodic Safety Update Reports (PSURs) / Periodic Benefit-Risk Evaluation Reports (PBRERs): Post-marketing safety evaluations.
  • Development Safety Update Reports (DSURs): Ongoing assessments during clinical development.

Discover why aggregate safety reporting is essential

Aggregate Safety Reporting - Vigilance - QbD Group (2)

Why is aggregate safety reporting essential?

Aggregate safety reporting is fundamental to ensuring product safety and regulatory compliance. Here’s why it’s indispensable:

  • Regulatory adherence: Meet global reporting requirements and avoid penalties or delays.
  • Risk management: Identify and address emerging safety signals early.
  • Product confidence: Provide stakeholders with clear evidence of a product’s safety and efficacy.
  • Streamlined processes: Efficiently manage and submit comprehensive safety data.

 

Discover how we can support you

How can we help?

QbD Group’s aggregate safety reporting services leverage advanced methodologies, including the PSO/ACO classification approach, to deliver precise and actionable insights. Here’s what we offer:

Report compilation and delivery

Report compilation and delivery

IND Annual Reports, CSRs, NDAs, PSURs/PBRERs, and DSURs tailored to meet your regulatory needs.

Advanced methodologies

Advanced methodologies

Utilizing PSO/ACO for classification and rule discovery to optimize post-marketing surveillance.

Regulatory expertise

Regulatory expertise

Ensure alignment with EMA, FDA, and other global authorities.

Comprehensive solutions

Comprehensive solutions

From data analysis to report submission, we manage the entire process.

Custom workflows

Custom workflows

Tailored reporting strategies that align with your operational goals.

Aggregate Safety Reporting - Vigilance - QbD Group (3)

Why partner with QbD Group?

Choosing QbD Group for aggregate safety reporting ensures:

  • Expert knowledge: Decades of experience in pharmacovigilance and regulatory compliance.

  • Innovative approaches: Advanced methodologies like PSO/ACO for superior safety data analysis.

  • Seamless service: End-to-end support from data collection to regulatory submission.

  • Proven track record: Successful delivery of safety reports for a wide range of products and markets.

Contact us
doc-mask

Related content

preview_image
Webinar

Unlocking Strategic Value in Drug Safety for Life Sciences Organizations

Explore how drug safety teams can transform into proactive benefit drivers with the right tools & resources in this webinar on demand.
Read more
preview_image
Whitepaper

The One-Vigilance strategic roadmap to corporate excellence

This whitepaper introduces the concept of One Vigilance within the context of the current drug safety landscape. Download now.
Read more
preview_image
Whitepaper

Ensuring compliance and quality in Pharmacovigilance

The whitepaper emphasizes the importance of a robust pharmacovigilance QMS and a well-maintained Pharmacovigilance System Master File (PSMF). Download now.
Read more
preview_image
Case study

Optimizing pharmacovigilance for a biotechnology leader

Discover how QbD Group improved pharmacovigilance for a global leader in biotechnology, ensuring regulatory compliance and patient safety.
Read more
Discover all
contact-mail

Get in touch

Looking for expert support in aggregate safety reporting?

With QbD Group, you gain a trusted partner who ensures compliance, streamlines your reporting processes, and provides actionable safety insights. Reach out today to see how we can assist you.

Vigilance_Get in touch